sb 239063 has been researched along with sb 242235 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adams, JL; Boehm, JC; Gallagher, TF; Garigipati, R; Griswold, DE; Hall, R; Kassis, S; Lee, JC; Sorenson, M; Webb, EF | 1 |
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
2 other study(ies) available for sb 239063 and sb 242235
Article | Year |
---|---|
Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.
Topics: Administration, Oral; Animals; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Imidazoles; Lipoxygenase; Liver; Mice; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Prostaglandin-Endoperoxide Synthases; Pyrimidines; Rats | 2001 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |